

Sun Young Yim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1123266/publications.pdf>

Version: 2024-02-01

63
papers

3,290
citations

516710

16
h-index

161849

54
g-index

64
all docs

64
docs citations

64
times ranked

7315
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. <i>Cell</i> , 2017, 169, 1327-1341.e23.	28.9	1,794
2	Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. <i>Clinical Cancer Research</i> , 2017, 23, 4441-4449.	7.0	342
3	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. <i>Gastroenterology</i> , 2019, 156, 1368-1380.e10.	1.3	296
4	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. <i>Nature Communications</i> , 2017, 8, 310.	12.8	169
5	BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 467-474.	2.8	47
6	The epidemiology of hepatitis B virus infection in Korea. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 945-953.	1.7	44
7	Clinical significance of APOB inactivation in hepatocellular carcinoma. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-12.	7.7	37
8	Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2021, 11, 14639.	3.3	37
9	Psychometric Hepatic Encephalopathy Score for the detection of minimal hepatic encephalopathy in Korean patients with liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1695-1704.	2.8	34
10	Clinical significance of YAP1 activation in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 111130-111143.	1.8	34
11	Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. <i>Gut and Liver</i> , 2021, 15, 284-294.	2.9	33
12	Risk Factors for Developing Hyponatremia During Terlipressin Treatment. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 607-612.	2.2	27
13	Low ARID1A Expression is Associated with Poor Prognosis in Hepatocellular Carcinoma. <i>Cells</i> , 2020, 9, 2002.	4.1	25
14	Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. <i>American Journal of Gastroenterology</i> , 2018, 113, 1167-1176.	0.4	23
15	The management and prognosis of patients with hepatocellular carcinoma: what has changed in 20 years?. <i>Liver International</i> , 2016, 36, 445-453.	3.9	22
16	Glutamine synthetase mediates sorafenib sensitivity in β -catenin-active hepatocellular carcinoma cells. <i>Experimental and Molecular Medicine</i> , 2018, 50, e421-e421.	7.7	21
17	Assessment and prediction of acute kidney injury in patients with decompensated cirrhosis with serum cystatin C and urine N-acetylgalactosaminidase. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 234-240.	2.8	17
18	Integrated Genomic Comparison of Mouse Models Reveals Their Clinical Resemblance to Human Liver Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 1713-1723.	3.4	14

#	ARTICLE	IF	CITATIONS
19	Prognostic significance of high metabolic activity in breast cancer: PET signature in breast cancer. <i>Biochemical and Biophysical Research Communications</i> , 2019, 511, 185-191.	2.1	14
20	Determinants of re�compensation in patients with hepatitis B virus�related decompensated cirrhosis starting antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 83-96.	3.7	13
21	The risk of perioperative adverse events in patients with chronic liver disease. <i>Liver International</i> , 2015, 35, 713-723.	3.9	11
22	Diagnostic performance of gadoxetic acid (Primovist)-enhanced MR imaging versus CT during hepatic arteriography and portography for small hypervascular hepatocellular carcinoma. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlook 10 Tf 5</i>	3.9	10
23	Three distinct genomic subtypes of head and neck squamous cell carcinoma associated with clinical outcomes. <i>Oral Oncology</i> , 2018, 85, 44-51.	1.5	11
24	Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 1840.	2.4	11
25	Gastrectomy for the treatment of refractory gastric ulceration after radioembolization with⁹⁰Y microspheres. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 300.	8.9	11
26	Feasibility and effectiveness of endoscopic irreversible electroporation for the upper gastrointestinal tract: an experimental animal study. <i>Scientific Reports</i> , 2021, 11, 15353.	3.3	10
27	Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 281-285.	8.9	10
28	Comparison on the Efficacy of Disinfectants Used in Automated Endoscope Reprocessors: PHMB-DBAC versus Orthophthalaldehyde. <i>Clinical Endoscopy</i> , 2011, 44, 109.	1.5	10
29	Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes. <i>Hepatology</i> , 2022, 76, 1634-1648.	7.3	10
30	Role of Hepatitis B Surface Antigen (HBsAg) in Identifying True Inactive HBsAg Carriers Infected With Genotype C Hepatitis B Virus. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 166-171.	2.2	9
31	NELFE-Dependent MYC Signature Identifies a Unique Cancer Subtype in Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2019, 9, 3369.	3.3	9
32	Spinal cord injury after conducting transcatheter arterial chemoembolization for costal metastasis of hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2012, 18, 316.	8.9	9
33	Genomic Perspective on Mouse Liver Cancer Models. <i>Cancers</i> , 2019, 11, 1648.	3.7	8
34	An Overview of the Genomic Characterization of Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1077-1088.	3.7	8
35	Expression of Hepatocyte Hepatitis B Core Antigen and Hepatitis B Surface Antigen as a Marker in the Management of Chronic Hepatitis B Patients. <i>Gut and Liver</i> , 2017, 11, 417-425.	2.9	8
36	Clinical Significance of Hepatitis B Virus Precore and Core Promoter Variants in Korean Patients With Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 61-68.	2.2	7

#	ARTICLE	IF	CITATIONS
37	How can we improve the performance of Model for End-Stage Liver Disease sodium score in patients with hepatitis B virus-related decompensated liver cirrhosis commencing antiviral treatment?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1641-1648.	2.8	7
38	Identification of novel susceptibility loci associated with hepatitis B surface antigen seroclearance in chronic hepatitis B. <i>PLoS ONE</i> , 2018, 13, e0199094.	2.5	7
39	Comparison of 2 curative treatment options for very early hepatocellular carcinoma. <i>Medicine (United States)</i> , 2019, 98, e16279.	1.0	7
40	Silence of Hippo Pathway Associates with Pro-Tumoral Immunosuppression: Potential Therapeutic Target of Glioblastomas. <i>Cells</i> , 2020, 9, 1761.	4.1	7
41	Non-Alcoholic Fatty Liver Disease Defined by Fatty Liver Index and Incidence of Heart Failure in the Korean Population: A Nationwide Cohort Study. <i>Diagnostics</i> , 2022, 12, 663.	2.6	7
42	Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients. <i>Cancers</i> , 2022, 14, 385.	3.7	6
43	How Should We Assign Large Infiltrative Hepatocellular Carcinomas for Staging?. <i>Cancers</i> , 2020, 12, 2589.	3.7	5
44	Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression. <i>PLoS ONE</i> , 2021, 16, e0255822.	2.5	5
45	Epidemiological and Clinical Characteristics of Pandemic Influenza (H1N1 2009). <i>Infection and Chemotherapy</i> , 2009, 42, 69.	2.3	5
46	Clinical implications of thoracic duct dilatation in patients with chronic liver disease. <i>Medicine (United States)</i> , 2020, 99, e19889.	1.0	4
47	Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 885-893.	1.6	4
48	Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C. <i>Gut and Liver</i> , 2016, 10, 808-817.	2.9	4
49	Rifampin-induced Pseudomembranous Colitis with Rectosigmoid Sparing. <i>Clinical Endoscopy</i> , 2011, 44, 137.	1.5	4
50	Differential Impact of Serum 25-Hydroxyvitamin D3 Levels on the Prognosis of Patients with Liver Cirrhosis According to MELD and Child-Pugh Scores. <i>Journal of Korean Medical Science</i> , 2020, 35, e129.	2.5	4
51	Identification of prognostic biomarker in predicting hepatocarcinogenesis from cirrhotic liver using protein and gene signatures. <i>Experimental and Molecular Pathology</i> , 2019, 111, 104319.	2.1	3
52	Pathological predictive factors for late recurrence of hepatocellular carcinoma in chronic liver disease. <i>Liver International</i> , 2021, 41, 1662-1674.	3.9	3
53	Molecular Subtypes and Genomic Signatures of Hepatocellular Carcinoma for Prognostication and Therapeutic Decision-Making. <i>Molecular and Translational Medicine</i> , 2019, , 109-123.	0.4	3
54	Two distinct stem cell-like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials. <i>Cancer Communications</i> , 2022, 42, 179-183.	9.2	3

#	ARTICLE	IF	CITATIONS
55	The LAW index as an accurate indicator of the initiation of antiviral treatment in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 208-214.	2.8	2
56	Validation study associating glutaminase promoter variations with hepatic encephalopathy in East Asian populations. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 901-907.	2.8	2
57	Subclinical Ascites Does Not Affect the Long-term Prognosis in Hepatitis B Virus-related Cirrhosis Patients Receiving Antivirals. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 676-685.	2.2	1
58	Abstract 3404: Clinical significance of APOB inactivation in hepatocellular carcinoma. , 2018, , .		1
59	Reply. <i>Hepatology</i> , 2015, 62, 653-654.	7.3	0
60	FRI-508-How reliable is initial liver resection before salvage liver transplantation and what are the predictors of dropout?. <i>Journal of Hepatology</i> , 2019, 70, e623.	3.7	0
61	THU-209-Dynamics of a transient elastography-based risk prediction model for hepatocellular carcinoma treated with antiviral therapy in chronic hepatitis B: A multi-center retrospective cohort study from the Korean Transient Elastography Study Group. <i>Journal of Hepatology</i> , 2019, 70, e255-e256.	3.7	0
62	Reply. <i>Hepatology</i> , 2019, 69, 924-924.	7.3	0
63	Fatal Hypersensitivity Reactions Induced by Re-Administration of Rifampin in an Immunocompetent Patient with Tuberculous Lymphadenopathy. <i>Korean Journal of Medicine</i> , 2012, 82, 115.	0.3	0